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Multiple Myeloma (MM) is malignancy of terminally differentiated plasma cells 
characterized by a marked heterogeneity of genetic lesions and clinical course. Despite 
significant efforts towards the development of risk stratification strategies for patients 
with Multiple Myeloma (MM), we are still limited in our capacity to molecularly 
predict the natural history of these patients. Recent molecular analyses have illuminated 
many aspects of the pathogenesis of this heterogeneous disease, although there remains 
an elemental view of the compendium of genetic elements driving MM initiation and 
progression and how such genetic alterations functionally contribute to specific aspects 
of disease pathobiology, prognosis and treatment responses. Indeed, despite 
considerable progress in the management of MM patients, many studies have shown 
that some genetic alterations especially t(4;14) translocation, loss of the short arm of 
chromosome 17, loss of the long arm of chromosome 13 and amplification of 
chromosome 1q21 remain associated with a poor outcome and represent independent 
adverse predictors of shorter progression free survival (PFS) and overall survival (OS). 
The 1q21 amplicon is among the most frequent chromosomal aberrations in patients 
with MM (about 40% of de novo MM) and is considered a highly poor-risk genetic 
feature correlated with disease progression and drug resistance; it spans approximately 
a region of 10-15 Mb containing a large number of possible candidate genes. To date 
the relevant genes on 1q21 remain unclear and the absence of focal amplifications 
involving this region strongly suggests that more than a single candidate may represent 
the driver event responsible for poor outcome of this group of MM patients. Thus, the 
identification of critical 1q21 ‘Achilles heel’ vulnerabilities may yield a comprehensive 
catalog of the potential therapeutic targets for these high risk MM and provide a 
rationale for patient stratification. In an effort to accomplish this goal, we first 
identified a high-priority list of 78 copy number-driven 1q21 MM-relevant genes. 
Then, we have designed a high-throughput systematic shRNA screen approach in vitro 
to identify 1q21 genes whose loss of function results in selective death and/or growth 
inhibition of MM cells carrying the 1q21 amplification. After excluding shRNAs that 
display citotoxic activity regardless 1q21 amplification, we defined 1q21 “Achilles 
heel” vulnerabilities as shRNA target genes whose down-regulation decreases 
substantially the percentage of GFP-positive MM cells with 1q21 amplification over a 
time of 7 days based on a GFP-competion assay. This assay provided a list of candidate 
genes implicated in survival or proliferation of MM cells with 1q21 amplification; 
MCL1, UBAP2L, INTS3, LASS2, KRTCAP2, and ILF2. By targeting these six genes 
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we performed secondary validation experiments in JJN3 and H929 MM cell lines, 
carrying 4 copies of 1q21 amplicon. The results of this secondary validation confirmed 
that the down-regulation of these genes caused an important decrease of proliferation 
and increase of apoptosis as well as growth cycle arrest. Further GEP analysis and 
clinical outcome studies revealed that only UBAP2L and ILF2 showed a significant 
prognostic value but in vivo validation studies on NOD-SCID mice identified only 
ILF2 correlated with in vivo survival. So our studies focused to investigate the role of 
ILF2 in 1q21 amplified MM. 
Nuclear Factor 45 (NF45) or ILF-2 is widely expressed in normal tissue with a 
predominant nuclear distribution. NF45/ILF2 associates with NF90/NF110 (ILF3) 
interacting with DNA and RNA. ILF2 and ILF3 contribute to gene regulation at 
different levels, transcription, splicing, nuclear exporting, but they are also involved in 
other important processes like mitotic control and DNA break repair. 
Down-regulation of ILF2 in MM cells with 1q21 amplification resulted in 
multinucleated phenotypes and abnormal nuclear morphologies that were associated 
with a significant accumulation of γH2AX foci and DNA damage response activation, 
increased sensitivity to Melphalan, DNA damaging agent, and impaired activation of 
DNA repair pathways. Experiments of immunoprecipitation combined with mass 
spectometry showed that ILF2 interacts with numerous RNA binding proteins directly 
implicated in DNA repair or regulation of DNA damage response by modulating 
alternative splicing and stability of specific pre-mRNAs. Accordingly, RNA-
sequencing analysis of ILF2-depleted MM cells, when compared to cells carrying 
scrambled shRNAs, identified specific changes in RNA splicing patterns before and 
after treatment with Melphalan. 
Thus, our findings have raised a new tight correlation between 1q21 amplification and 
DNA damage response. We identified ILF2 as a key driver of this interaction, and our 
findings support the development of strategies designed to modulate ILF2 expression in 
patients with high-risk MM carrying 1q21 amplification providing personalized 
therapies for patients who do not benefit from recent treatment improvements. 
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Multiple Myeloma  
Multiple Myeloma (MM) is a genetically complex disease that is becoming more 
common in today’s ageing population. MM is a Plasma-Cell (PC) malignancy 
characterized by the accumulation of terminally differentiated clonal PCs in the Bone 
Marrow (BM), the production of a monoclonal immunoglobulin (Ig) detectable in 
serum and/or urine and the presence of lytic bone lesions {4}. In the Western countries 
MM accounts for approximately 2% of all cancer-related deaths, and in the USA 
constitute approximately 20% of all hematological malignancies {1}. The incidence of 
MM increases with age and the patient median age with MM is 65 years, but 3% of 
them are younger than 40 years {2}. MM remain an incurable disease and the median 
length of survival after diagnosis is three to five years. Although some evidence for 
genetic predisposition, genetic background and environmental role remain to be 
clarified {3}. 
Clinical features and pathogenesis of multiple myeloma 
Multiple myeloma is caused by the growth of a malignant plasma cell clone in the bone 
marrow, leading to severe clinical symptoms that include hypercalcaemia (occurring in 
25% of patients), renal dysfunction (50%), anemia (70%), and bone disease (frequently 
referred to by the acronym CRAB) which represent evidence of end organ failure {4}. 
The presence of one or more of these four markers related to the underlying plasma cell 
disorder is required for the diagnosis of the disease.   
The initiation and progression of myeloma at the present it is believed developing via 
multistep process where an initiating hit is required to immortalize a Myeloma-
Propagating Cell (MPC) that is destined to acquire additional genetic hits over time {5} 
(Figure 1). 
 Figure 1: Initiation and progression of Myeloma. 
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In many instances MM is preceded by a pre-malignant tumor called Monoclonal 
Gammopathy of Undetermined Significance (MGUS), which is the most common 
lymphoid tumor in humans, occurring in approximately 3% of individuals over the age 
of 50{6}. The transition from MGUS to Plasma Cell Leukemia (PCL) has been 
traditionally represented as a linear pathway but more likely the pathway to myeloma is 
through branching pathways. A post-Germinal Centre (GC) B cell receives a genetic hit 
which immortalizes the cell and starts the transition to the indolent phase of MGUS. 
More genetic hits which confer a survival advantage and are acquired over time, allow 
to MGUS clones to pass through the other disease phases of SMM (Smoldering 
Multiple Myeloma), myeloma, and PCL. Clonal evolution develops through branching 
pathways whereby numerous ecosystems composed of multiple subclones exist at each 
disease phase, as represented by the differing shapes. At the end of this process, 
proliferative clones no longer become confined to the bone marrow and expand rapidly 
as a leukemic phase. At each disease phase, the precursor clones are present only at a 
low level as they have been outcompeted by more advantageous clones. This multistep 
process permits myeloma to have various recognizable clinical phases, distinguished by 
biological parameters, along its development (Table 1).  
 
MGUS (Monoclonal Gammopathy of Undetermined Significance) 
• M-protein in serum <30 g/L 
• BM clonal PC <10% and low level of PC infiltration in the trephine biopsy (if done) 
• No evidence of other B cell proliferative disorders 
• No MM-related organ or tissue impairment (no end organ damage, including bone lesions) 
 
SMM (Smoldering Multiple Myeloma) 
• M-protein in serum >30 g/L and/or BM clonal PC >10% 
• No evidence of other B cell proliferative disorders 
• No MM-related organ or tissue impairment (no end organ damage) or symptoms 
 
MM (Multiple Myeloma) 
• M-protein in serum and/or urine (M protein in most cases is >30g/L (>25g/L sometimes used for IgA) 
and >1g/24hr of urine light chain but some patients with symptomatic MM have lower than these) 
• BM clonal PC or plasmacytoma (Monoclonal PC usually exceed 10% of nucleated cells in the BM but 
no minimal level is designated because about 5% of patients with symptomatic MM have <10% BM PC)  
• No evidence of other B-cell proliferative disorders 
• Related organ or tissue impairment (no end organ damage, including bone lesions) 
 
Plasmacytoma 
 
Solitary plasmacytoma of the bone 
• No M-protein in the serum and/or urine (a small M-component may sometimes be present) 
• Single area of bone destruction due to clonal PC 
• BM not consistent with MM 
• Normal skeletal survey (and magnetic resonance imaging (MRI) of spine and pelvis if done) 
• No MM-related organ or tissue impairment (no end organ damage other than solitary bone lesions) 
 
Extramedullary plasmacytoma 
• No M-protein in serum and/or urine (a small M-component may sometimes be present) 
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• Extramedullary tumour of clonal PC 
• Normal BM 
• Normal skeletal survey 
• No MM-related organ or tissue impairment (no end organ damage other than solitary bone lesions) 
 
Non-secretory MM 
• No M-protein in serum and/or urine with immunofixation 
• BM clonal plasmacytosis >10% or plasmacytoma 
• Related organ or tissue impairment (end organ damage, including bone lesions) 
 
Plasma cell leukemia 
• Absolute PC count in peripheral blood >2.0 x 109/l 
• Peripheral blood differential white cell count with >20% PC 
 
Amyloidosis 
• Presence of an amyloid-related systemic syndrome 
• Positive amyloid staining by Congo red in any tissue (e.g. fat aspirate, BM, organ biopsy) 
• Evidence that amyloid is light chain-related established by direct examination of the amyloid 
• Presence of a monoclonal PC disorder 
Myeloma related organ or tissue impairment (CRAB) 
Hypercalcemia (serum calcium >11.5mg/dl) (C), renal insufficiency (serum creatinine >177µmol/L) (R), 
anemia (hemoglobin <10g/dl) (A); bone lesions: lytic lesions or osteoporosis with compression fractures 
(MRI may clarify) (B). Other: symptomatic hyperviscosity, amyloidosis, recurrent bacterial infections (> 
two episodes in 12 months) {136}. 
 
Table 1: Diagnostic criteria for PC neoplasms {135}. 
 
MGUS is an indolent, asymptomatic, premalignancy phase characterized by a small 
clonal population of plasma cells within the bone marrow of <10% {6}. MGUS has a 
prevalence of >5% in adults aged over 70 and a progression risk to myeloma quantified 
at 1% per year {7,8}. The next asymptomatic phase is SMM that is distinguished from 
MGUS by a greater intramedullary tumour cell content of >10% and an average risk of 
progression to myeloma of 10% per year for the first five years {9}. Next, myeloma 
itself is recognized; whereby malignant clones cause clinically relevant end-organ 
damage including the features of CRAB. There are no unequivocal genetic or 
phenotypic markers that distinguish MGUS from MM tumour cells, so that it is not 
possible to predict if and when an MGUS tumour will progress to MM. Also, it remains 
unclear to what extent intrinsic genetic or epigenetic changes in MGUS tumour cell 
versus extrinsic changes in non-tumour cells affect progression. The final phase is PCL, 
an aggressive disease end-point characterized by the existence of extramedullary clones 
and rapid progression to death (Figure 2). Some of these extramedullary multiple 
myelomas can establish immortalized cell lines in vitro.  
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Figure 2: Progression through the different stages of Multiple Myeloma. 
 
Multiple myeloma cells are the transformed counterparts of post-germinal center bone 
marrow plasmablasts/plasma cells arising from malignant transformation of plasma cell 
or their precursors {9}. 
Initially, multiple myeloma is confined to the bone marrow (intramedullary), but with 
time the tumour can acquire the ability to grow in extramedullary locations (such as 
blood, pleural fluid and skin). The strong association with the stromal cells of the BM 
makes MM cells phenotypically similar to long-lived PCs but also the 
immunophenotype looks like that of normal long-lived bone marrow PC (CD19-CD20-
CD45-CD138+){1}. Despite to them MM is able to proliferate at very low rate, usually 
with no more than a few percent of cycling cells until advanced stages of MM {10}. 
 
Deregulation of myeloma cellular pathways and processes  
Several signaling pathways deregulated in MM play crucial roles in promoting growth, 
survival, adhesion, migration, immortalization, angiogenesis, and drug resistance {82}. 
Other cellular processes such as DNA repair, RNA editing, protein homeostasis, and 
cell differentiation may also contribute towards myeloma genesis through aberrant 
functioning. 
NF-kB pathway 
The importance of NF-kB pathway in MM is supported by the evidence that at least 
50% of cases and 20/44 HMCLs show the NF-kB pathway constitutively active {67;68}. 
Moreover also several studies suggest the relevance of NF-kB signaling in MM, by the 
nuclear presence of NF-kB in MM cells and the sensitivity of some MM cell lines to 
NF-kB inhibition {83,84}. Interestingly, not only in plasma cells but also in surrounding 
bone marrow stromal cells the pathway of NF-kB can be upregulated following 
production of IL6, BAFF, or APRIL, known growth factors for and activators of NF-
kB in MM {83}. 
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In myeloma cell lines and patient samples different mechanisms may deregulate NF-kB 
pathway both inactivating pathway suppressors due to deletions and/or mutations and 
hyperactivating NF-kB target gene expression including NF-kB-inducing kinase (NIK), 
TRAF3, CYLD, BIRC2/BIRC3, CD40, NFKB1, or NFKB2 {67}. Moreover whole 
genome sequencing (WGS) and whole exome sequencing studies suggested a broader 
role of NF-kB signaling by discover of 10 novel point mutations and 4 structural 
rearrangements affecting 11 members of the NF-kB pathway {60}. Nevertheless, 
although the importance of deregulated NF-kB pathway in myeloma pathogenesis is 
attested, the prognostic impact for many of the implicated genes are yet to be fully 
investigated. 
The Mitogen Activated Protein Kinase (MAPK) pathway 
The MAPK pathway, involved in cell differentiation, proliferation, and survival, may 
be stimulated through a variety of inflammatory cytokines, including TNF-α, IL-6, and 
IGF-1, which alternately activate the downstream kinase cascades RAS, RAF, MEK, 
and MAPK influencing gene expression. N-RAS and K-RAS are the two dominant 
oncogenes in the MAPK pathway frequently mutated in myeloma. The prevalence of 
activating N- or K-RAS mutations is nearly 20–35% in the newly diagnosed MM 
tumors {85} and 45% in HMCLs {86}. It should be noticed that the prognostic impact 
between the two different forms of RAS could not be equal because some studies have 
shown that N-RAS mutations were more common that K-RAS mutations {85}. This 
represents an important finding if genetic lesions are used to define risk. Patients with 
RAS mutation have more aggressive disease features and significantly shorter overall 
survival and progression free survival despite similar response to therapy.  
Interestingly, the incidence of RAS mutation in MGUS is less than 5% compared to 
MM 60}, this evidence is consistent with the hypothesis that RAS mutation might be an 
important progression event from MGUS to MM {87}. Thus because RAS mutation 
represents the single most frequently mutated gene in myeloma, therapeutic inhibitors 
in its pathway are searching. 
The JAK-STAT pathway 
Nearly 50% of myeloma samples and a quote of surrounding BM stromal cells have 
JAK-STAT pathway constitutively activated {88,89}. JAK-STAT activation seems 
occurring mainly through autocrine and paracrine stimulation of IL-6, an important 
cytokine in myeloma genesis that regulates growth and survival of MM cells {90}. 
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Indeed the activation of this pathway leads to hyperactivity of the transcription factor 
STAT3, which results in elevated expression of the antiapoptotic protein                  
Bcl-xL/BCL-2 {91}. On the other side the STAT3 knockdown or IL-6 receptor blockade 
may cause apoptosis in some HMCLs but only in absence of the BM microenvironment 
{92}. This finding indicates that IL-6R/STAT3 signaling is dispensable within the 
context of the BM microenvironment, which might stimulate IL-6–independent 
pathways that protect MM cells from apoptosis {92}. 
The Phosphatidylinositol-3 Kinase (PI3K) Pathway  
It has been suggested that the dysregulation of PI3K pathway may be significant in 
myeloma cells growth and survival as a number of cytokines including IL-6 and IGF-1 
can be activate it via phosphorylation of the serine-threonine-specific kinase AKT. The 
latter is an indicative marker of PI3K activity and its phosphorylation is detected in 
approximately 50% of cases. Afterwards downstream targets of AKT including mTOR 
and GSK-3β can be activated and influence many processes including cell proliferation 
and apoptosis resistance {93}. Despite of MAPK pathway, the PI3K pathway is not 
frequently mutated in myeloma {94}. Anyway the pathway can potentially be 
therapeutically targeted at different points such as inhibition of 
phosphorylation/activation of AKT and inhibition of PI3K itself  {95}. 
 
Translocation and cyclin D (TC) classification 
Cyclin D genes are expressed at low levels in quiescent cells, while in response to 
growth factors they are transcriptionally up-regulated and expressed in all proliferating 
cells. Despite the very low proliferative activity observed in PC from MGUS/SMM and 
MM patients, the level of CCND1, CCND2 or CCND3 mRNA in all these tumors was 
found to be relatively high compared with the level of CCND2 mRNA expression in 
healthy proliferating PC {96} making the dysregulation of a cyclin D gene a unifying 
oncogenic event. This up-regulation of cyclin D genes is caused by either IgH 
translocations or other, unknown mechanisms. 
Gene expression profiling can detect the expression levels of CCND1, CCND2, and 
CCND3 and simultaneously identify spiked expression of genes deregulated by 
primary IgH translocations. Supervised analysis of gene expression profiles provided 
the basis for a molecular classification of MM: the translocation and cyclin D (TC) 
classification (Table 2). 
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Group 
 
 
Primary        
Translocation 
 
Gene at Breakpoint 
    
   D-Cyclin            Ploidy                 Proliferation  
                                                               Index 
 
Bone disease 
(% MRI Pos) 
 
Frequency 
(%) 
 
Prognosis 
6p21 6p21 CCND3 D3 NH Average 100 3    ? Good 
11q13 11q13 CCND1 D1 D, NH Average 94 16 Good 
D1 None None D1    H Low 86 34 Good 
D1+D
2 
None None D1 and D2 H High 100 6    ? Poor 
D2 None None D2 H, NH Average 67 17 ? 
None None None None NH Average 100 2     ? Good 
4p16 4p16 FGFR3/MMSET D2 NH O H Average 57 15 Poor 
maf 16q23 c-maf D2 NH High 55 5 Poor 
 20q11 mafB     2  
Abbreviations: MRI, magnetic resonance imaging; pos, positive; D, diploid; H, hyperdiploid; NH, nonhyperdiploid. 
 
Table 2: Translocation and Cyclin D (TC) groups. 
 
Thus Bergsagel et al. developed the translocation/cyclin D (TC) classification (Figure 
3), subdividing myeloma patients into 8 subgroups based on the presence of genes 
(in)directly dysregulated by translocations and cyclin D overexpression: (1) 4p16 
tumors (15%) expressing high levels of CCND2 and MMSET (and in most cases 
FGFR3) as a result of the translocation t(4;14); (2) MAF tumors (7%) expressing the 
highest levels of CCND2 and showing high levels of either c-MAF or MAFB, 
consistent with the possibility that both MAF transcription factors up-regulate the 
expression of CCND2; (3) 11q13 (16%) and (4) 6p21 (3%) tumors expressing high 
levels of either CCND1 or CCND3 as a result of an IgH translocation; (5) D1 tumors 
(34%) ectopically expressing low to moderate levels of CCND1 despite the absence of 
a t(11;14) translocation; (6) D1+D2 (6%) expressing both CCND1 and CCND2. (7) D2 
tumors (17%) were a mixture of tumors expressing CCND2; (8) none (1%) expressed 
no D-type cyclins. The TC classification did not clearly identify patients with HRD 
MM. HRD tumors were mainly found in the D1 and D1+D2 groups. D1 and D2 HRD 
MM appeared to have a higher incidence of proliferative disease compared to D1 HRD 
MM characterized by a low proliferative index. However, no differences in survival 
were noted between the two groups {96}. 
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Figure 3: Dysregulation of one of the three cyclin D can be a consequence of Ig translocations (solid 
arrow) or by an unknown mechanism (dashed arrow){137}. 
 
Genetic architecture and disease progression 
At the cytogenetic level MM genome is complex and more reminiscent of epithelial 
cancers than of more simple leukemia. Many of the genetic lesions that lead to MM 
have been defined, and can be categorized as inherited variation, traslocations, copy 
number abnormalities, mutations, methylation, and miRNA abnormalities. 
Chromosomal translocations 
Multiple Myeloma is essentially a complex genetic disease characterized by marked 
karyotype instability and almost all cases of MM are cytogenetically abnormal {11}. 
Like a normal long-lived plasma cell, a myeloma cell undergoes three developmentally 
regulated changes in the DNA structure of the immunoglobulin heavy chain and light 
chain (IgH and IgL) loci, including V(D)J recombination of its IgH and IgL genes, 
somatic hypermutation of the IgH and IgL variable regions, and productive IgH switch 
recombination to another IgH isotype {12}. As result of having undergone these 
processes, the Ig genes in plasma cells (PCs) from myeloma patients are characterized 
by heavily mutated VH regions with no intraclonal variation and carry isotype-switched 
IgH genes (IgG or IgA) {13}, and also chromosomal translocations targeting the 
immunoglobulin H (IgH) locus (at 14q32.3), and less frequently the IgL locus (2p12, or 
22q11) {14,15,16}. These aberrant rearrangements juxtapose oncogenes into the proximity 
of the powerful IGH enhancers, driving abnormal expression of the translocated 
oncogenes. This enables the cells to survive and proliferate, resulting in 
immortalization of the malignant cell clone. The translocations of the IGH at 14q32 are 
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associated to the non hyperdiploid myeloma subtypes distinguished from the 
hyperdiploid myeloma subtypes which are characterized by trisomies of certain odd 
numbered chromosomes, 3, 5, 7, 9, 11, 15, 19, and 21 with a low prevalence of 
chromosomal translocations (Figure 4). 
 
Figure 4: In MM two distinct pathways have been recognized: a nonhyperdiploid (nonHRD) (black 
triangle) that usually includes one of seven recurrent IgH translocations as an early event and a 
hyperdiploid (HRD) pathway (white triangle) which is associated with multiple trisomies of odd 
numbered chromosomes. 
 
Hyperdiploid and non hyperdiploid changes appear to represent early or even initiating 
mutagenic events that are followed by secondary aberrations including copy number 
abnormalities, additional translocations, mutations, and epigenetic modifications which 
lead to plasma cell immortalization and disease progression. 
Primary translocation 
Karyotypic instability begins from the earliest phase of MM and increases with stage 
disease. The IgH translocations can be observed in approximately 50% of patients with 
MGUS or SMM, 55%-70% of intramedullary MM, 85% in primary PLC and > 90% of 
myeloma cell lines {1; 17,18,19}. The translocations involving the IgH locus at 14q32 have 
five recurrent partner chromosomes: 11q13 (CCND1, the most common), 4p16.3 
(MMSET/FGFR3), 6p21 (CCND3), 16q23 (c-MAF), and 20q11 (MAFB){20} and they 
are identified in approximately 40% of MM tumors representing markers for distinct 
myeloma subtypes with important prognostic implications. 
The breakpoints of these translocations mostly occur within or near switch regions, and 
sometimes within or near VDJ sequences, suggesting that they could be mediated by 
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mistakes in IgH switch recombination or somatic hypermutation. There is no evidence 
that IgH switch recombination or somatic hypermutation mechanisms are active in 
normal PC or PC tumors, so it is presumed that these translocations usually represent 
primary, perhaps initiating, oncogenic events as normal B cells pass through germinal 
centers.  
 
MMSET/FGFR3 translocation group 
The t(4;14), found in 15% of myeloma cases using FISH analysis, has been associated 
with an adverse prognosis in a variety of clinical settings {21,22}. Pathologically the 
juxtaposition next to the IGH 3’ enhancers, leads to the overexpression of two genes, 
Fibroblast Growth Factor Receptor 3 gene (FGFR3) on der(14) and the Multiple 
Myeloma SET domain gene (MMSET) on der(4){22}. The up-regulation of FGFR3 
implies the ectopic expression of the FGFR3 tyrosine kinase receptor, an aberration 
with an unclear role in myeloma genesis.  Gene expression profiling and RT-PCR 
analysis have shown that only 70% of the MM with t(4;14) display a simultaneous 
overexpression of MMSET and FGFR3. As approximately 30% of t(4;14) tumors are 
imbalanced due to lack of FGFR3 expression following the loss of the der(14), the 
pathogenic role of FGFR3 is somewhat in doubt although in some cases der(14) is 
present and other mechanisms account for the loss of FGFR3 expression {19;23}. 
Furthermore, in these 30% lacking FGFR3 expression, the adverse prognosis of t(4; 14) 
remains{21}, lending support for the role of the second gene MMSET. MMSET, 
encoding a chromatin-remodelling factor with histone methyltransferase (HMT), is 
overexpressed in all MM harboring the t(4; 14) which represents the only known 
mechanism that dysregulates MMSET{24}. Sometimes rare tumors with t(4;14) can 
acquire kinase-activating mutations of the dysregulated FGFR3 during tumor 
progression, and there is evidence that the survival and proliferation of these tumours is 
dependent on the mutated FGFR3{25,26}. Although epigenetic regulation and a role in 
DNA repair have been suggested, like FGFR3, the exact role of MMSET in the 
pathogenesis of MM is still unclear {27,28}. 
 
Cyclin D translocation group 
The t(6;14) is a translocation present in only 2% of myeloma patients and acts 
upregulating directly the CCND3 gene via juxtaposition to the IGH 3’ enhancers {29} 
while t(11;14) is more common, observed in approximately 17% of myeloma patients 
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and also directly upregulates a cyclin D gene, CCND1{30}. Gene expression profiling 
studies have shown that the overexpression of CCND3 and CCND1 results in a 
clustering of downstream gene expression suggesting that activation of these two genes 
results in the dysregulation of common downstream transcriptional programs {24}. 
Unlike t(4;14), the overall prognostic impact of these two translocations is neutral 
although t(11;14) patients show considerable heterogeneity and in some cases the 
translocation may manifest with an aggressive phenotype such as PCL{31}. 
 
MAF translocation group 
The t(14;16) and t(14;20) both result in increased expression of a MAF family 
oncogene and combined are identified in 5–10% of presenting myeloma cases. In 
detail, t(14;16) results in overexpression of c-MAF, a transcription factor which 
upregulates a several genes like CCND2 and other genes (ITGB7, ARK5) that appear 
to affect the phenotype of the tumor cells, and its potential interactions with the bone-
marrow microenvironment {32,33}. 
The t(14;16) is commonly associated with a poor prognosis {22;34}, although this 
concept has recently questioned by retrospective multivariate analysis on 1003 newly 
diagnosed myeloma patients which showed t(14;16) not to be prognostic {35}, t(14;20) 
is the rarest translocation involving the IGH locus and results in upregulation of the 
MAFB gene. It seems that also MAFB could deregulated the same downstream targets 
of cMAF because MAFB overexpression showed a similar gene expression profile to 
that seen with cMAF {24}. Notably, t(14;20) is associated with a poor prognosis when 
present in myeloma but correlates to long-term stable disease when found in MGUS 
and SMM {36}. This observation suggests that MAF deregulation alone is not 
responsible for the adverse outcomes but that additional genetic events are required. 
Secondary Translocations  
As myeloma tumors become more proliferative at later stage of disease, secondary 
translocations occur but in contrast to primary translocations, they represent class-
switch recombination independent events that do not involve B cell specific processes. 
The most frequent secondary translocation is t(8;14) observed in only 3% of MM {37,38}. 
The gene typically deregulated is MYC and its overexpression is linked directly to late 
disease stages and indirectly to a poor prognosis via a strong correlation to high levels 
of an established indicator of a poor prognosis, the serum 𝛽2-microglobulin       
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(S𝛽2M) {38,40}. The frequency of MYC overexpression from secondary translocations 
reflects its role as a progression event, as it is absent o rare in MGUS but seen in 15% 
of myelomas, 50% of advanced disease and 90% of HMCL (Human MM Cell Line) 
{38;41}. These secondary events often include unbalanced and complex translocations 
and insertions that can involve three chromosomes, sometimes with associated 
amplification, duplication, inversion, or deletion. Thus MYC rearrangements are 
thought to represent a very late progression event that occurs when MM tumors are 
becoming less stromal-cell-dependent and/or more proliferative {1}. 
Other IgH translocation partners have been identified in approximately 20% of MGUS 
and MM tumors {17,18,19}. These other partners, who are poorly characterized, appear to 
be mostly non-recurrent or rare. These translocations seem to share the structural 
complexity and lack of IgH switch region involvement observed for MYC 
translocations, suggesting that they usually represent secondary translocations, which 
can occur at any time during tumor progression, including MGUS. Translocations 
involving an Igλ locus occur in about 10% of MGUS tumors, and approximately 20% 
of advanced MM tumors or HMCLs {1;17}. Translocations involving an Igκ locus are 
rare, occurring in only a few percent of MM tumors. Nearly half of IgL translocations 
in advanced MM tumors or HMCL target a MYC gene. Significantly, although all 
HMCLs analyzed have either an IgH or IgL translocation, whereas approximately 30% 
of MM tumors and 45% of MGUS tumors do not have either an IgH or IgL 
translocation. Surprisingly, however, two independent Ig translocations have been 
found in 5% of MGUS tumors, 25% of advanced MM tumors, and 58% of HMCL, 
consistent with an accumulation of secondary Ig translocations during tumor 
progression {17}. 
Copy number variations in Myeloma 
Copy number variations result from gains and losses of DNA and are common events 
in myeloma. These gains and losses can be both focal or of an entire 
chromosome/chromosome arm. In general, losses of DNA contribute to malignancy 
through loss of tumour suppressor genes, whereas gains are pathogenic through 
oncogene overexpression/activation. 
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Aneuploidy 
Approximately 50% of myeloma cases are hyperdiploidy ((HD) 48-75 chromosomes) 
involving trisomies of the odd numbered chromosomes 3, 5, 7, 9, 11, 15, 19, and 21, 
but only infrequently (<10%) have one of the recurrent IgH translocations {42}. More 
common in aged patients and associated with a high incidence of bone disease; 
hyperdiploidy confers a relatively favorable prognosis in the majority of cases {43}. The 
remaining cases, non-hyperdiploidy (NHD) subtypes, can be hypodiploid (up to 44/45 
chromosomes), pseudodiploid (44/45 to 46/47) or near tetraploid (more than 74), and 
usually (∼70%) show one of the recurrent IgH translocations{44}. 
In contrast to the selective event of recurrent IgH translocations in NHD tumors, other 
genetic events (17p loss or p53 mutations, RAS mutations, secondary Ig translocations, 
MYC translocations) often occur with a similar prevalence in HD and NHD tumors, 
while loss of chromosome 13 occurs in 72% of NHD tumors but only 37% of HD 
tumors, which is explained partially by the increased prevalence of t(4;14) and t(14;16) 
in NHD tumors{45}.  
For tumors that are hyperdiploid but have one of the recurrent translocations, most 
often a t(4;14), we do not know whether hyperdiploidy occurred before or after the 
translocation since the underlying mechanism to generate hyperdiploidy is unknown. 
However, one can make the hypothesis, based on what is suggested to occur in 
hyperdiploid acute lymphoblastic leukemia, of a single catastrophic mitosis results in 
the gain of whole chromosomes rather than their serial accumulation over time {46}. Not 
only the underlying mechanism but also the consequence of hyperdiploidy towards 
myeloma genesis is poorly understood. Anyway recent GEP studies have demonstrated 
that hyperdiploid myeloma is characterized by overexpression of genes involved in 
protein biosynthesis, specifically ribosomal protein genes representing end-points in 
important signaling pathways of myeloma biology as MYC, NF-𝜅B, and MAPK. This 
finding raises the possibility that one consequence of this protein biosynthesis profile in 
hyperdiploid myeloma is deregulation and overproduction of oncogenic proteins {47}. 
 
Loss of Chromosome 13/13q14  
Approximately 50% of myeloma cases {19; 48, 49,50} and 40-50% of MGUS {18;48} present 
deletion of chromosome 13 suggesting that often this is an early event in the 
pathogenesis. In around 85% of cases, deletion of chromosome 13 occurs like a whole-
chromosome monosomy {51,52} or loss of the q arm, whereas various interstitial 
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deletions have been observed in the remaining 15% of cases, keeping a level of gene 
function{51}. Nevertheless the identification of key genes contributing to myeloma 
pathogenesis is a challenging, molecular studies have shown that the tumour suppressor 
gene RB1 is significantly underexpressed in del(13/13q) resulting in inferior negative 
cell cycle regulation{53}. The prognostic impact of del(13/13q) is also a challenging 
because it is frequently associated with other high-risk lesions, like t(4;14) in 
approximately 90% of cases{54}. When del(13/13q) is detected via conventional 
cytogenetics there is a link to poor survival{55,56}, whereas when detected via FISH, and 
in the absence of coexisting high-risk lesions, the linkage with survival is lost{57;31}. 
This finding suggests that the historical link between del(13/13q) and a poor prognosis 
come from its association with high-risk lesions. 
 
Loss of 1p  
Around 30% of myeloma patients show whole arm deletion or interstitial deletions of 
the 1p chromosome. This deletion is associated with a poor prognosis {53;58,59} but 
molecular genetic studies have revealed that two regions of 1p, 1p12, and 1p32.3 are 
mainly important in myeloma pathogenesis when deleted. In detail 1p12 region 
contains the candidate tumour suppressor gene FAM46C whose function is unknown, 
although its expression seems correlated to factors involved in protein translation {60}. 
FAM46C seems an important gene in myeloma as it has been shown to be frequently 
mutated and also independently correlated to a poor prognosis {53;58;60,61}. 1p32.3 
contains the two target genes, FAF1 and CDKN2C. The latter is a cyclin-dependent 
kinase 4 inhibitor involved in negative regulation of the cell cycle, whereas FAF1 
through the Fas pathway encodes a protein involved in initiation and/or enhancement of 
apoptosis. Homozygous deletion of 1p32.3 is associated with prognosis based on the 
treatment to whom patients are subjected, for those who received ASCT the prognosis 
is poor, for the other ones its prognostic impact is neutral {58}. Although some 
evidences place CDKN2C like the influential gene lost through homozygous 1p32.3 
deletion {58;62}, the significance of FAF1 related to CDKN2C remains to elucidate as 
most of deletions lost both genes that lie in close proximity. 
 
Loss of 17p 
Most of chromosome 17 deletions involve the whole p arm in approximately 10% of 
new myeloma cases but the frequency of mutations appears to increase with disease 
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stage becoming approximately of 30% in PCL{19;63}. It is believed that the relevant gene 
deregulated in del(17p) being the tumour suppressor gene TP53 but there is not 
definitive evidence that the critical chromosome 17p loss is TP53. However there are 
some findings that could be able to support this hypothesis. In GEP studies myeloma 
samples with monoallelic 17p deletions express significantly less TP53 compared to 
non-deleted samples {53}. Furthermore, patients that do not have the del(17p) the rate of 
TP53 mutation is <1%, whereas in those with del(17p) this rises to 25–37% {64}.  
The TP53 gene maps to 17p13 and is known that it is a transcriptional regulator of cell 
cycle arrest, DNA repair, and apoptosis in response to DNA damage. In myeloma, 
del(17p) represents the most important molecular prognostic indicator as it linked to an 
aggressive disease phenotype, a greater degree of extramedullary disease, and short 
survival{19;31;65}. Furthermore, 65% of HMCLs show TP53 deficiency, further 
suggesting its relevant role in extramedullary disease. Most of PCL cases have 
abnormalities in TP53 gene so it is assumed that PCL might be largely a consequence 
of TP53 dysfunction {63}, but it should be noticed that there is no direct biological 
evidence supporting this hypothesis, and the genetic consequences of the deletion need 
to be further clarified. 
 
Other Chromosomal Losses  
Many other chromosomal losses are observed in myeloma, and like in the deletions of 
1p, 13/13q, and 17p, they are “driver” lesions that contribute to myeloma pathogenesis 
because the regions involved contain tumor suppressor genes. An important deletion, 
observed in the 7% of myeloma cases, concerns chromosome 11q where the tumour 
suppressor genes BIRC2 and BIRC3 are located. More common is the del(14q), the site 
of the tumor suppressor gene TRAF3, founded in 38% of cases {53}. Another common 
deletion is the 16q, seen in the 35% if myeloma cases, that harbor the tumor suppressor 
genes CYLD and WWOX{53}. All of these genes, except WWOX implicated in 
apoptosis {65}, are involved in the nuclear factor-kB (NF-kB) pathway, indicating that 
up-regulation of NF-kB signaling is important in myeloma pathogenesis {53;67,68}. 
Del(6q) and del(8p), seen in 33% and 19-24% of cases, are other two common 
chromosomal arm deletions {53;69,70} but the significance of del(6q) towards survival is 
still not clear. Instead del(8p) acts as an independently poor prognostic factor for both 
progression free survival (PFS) and overall survival (OS) {69}. Furthermore, the tumor 
necrosis factor-related apoptosis-inducing ligand receptor genes (TRAIL-R1 and 
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TRAIL-R2) located on 8p, show a down-regulation due to del(8p) {71}. In vitro, TRAIL 
was shown to play pivotal roles in inducing apoptosis in HMCLs and in immune 
surveillance. Thus, mutation of TRAILR1 and TRAIL-R2 may contribute to the loss of 
its apoptotic function and provides a growth advantage to cancer cells {70}. 
 
Gain of 1q  
Comparative genomic hybridization (CGH) and fluorescence in situ hybridization 
(FISH) have revealed chromosomal gains of 1q, which may occur as iso-chromosomes, 
duplications, or jumping translocations {110}. Nearly 35-40% of myeloma cases show 
the gain of the chromosome 1q arm (+1q) representing one of the most frequent 
chromosomal aberrations observed in MM {53;61}. These gains are concentrated 
substantially in those tumours that have a t(4;14) or t(14;16), or an high proliferation 
rate {72,73}. The 1q21 amplification is related to an advanced phenotype of MM and 
associated with disease progression {74}. Indeed the incidence of Amp1q21 increases 
with stage disease; 0% in MGUS, 45% in SMM, 43% in newly diagnosed MM, 72% in 
relapsed MM, and 91% in human myeloma cell lines {73}. It is considered a highly-poor 
risk genetic feature correlated with a poor prognosis in newly diagnosed MM and a 
shortened post-relapse survival and may be central to progression of plasma cell 
dyscrasias {73}. There was no notable improvement in survival of patients with 1q21 
gains when treated with chemotherapy incorporating bortezomib, implying that 1q21 
gains might be linked to bortezomib resistance and drug resistance {75,76}.  
 
 
 
 
 
 
 
 
 
 
Introduction 
 
22 
 
1q21 region: copy number aberrations and target candidate 
genes in multiple myeloma  
Chromosome 1, one of the largest chromosomes, has 3141 genes and many overlapping 
coding sequences. This is the reason why it represents a likely candidate for genetic 
events that lead to malignant transformation{110}. The gain of the 1q21 region is a 
cytogenetic marker for high-risk multiple myeloma, occurs frequently, about 40% of 
cases, and is often found in proliferative relapsed and/or refractory disease {75;77;97}. 
Many studies have shown that those genetic alterations represent independent adverse 
predictors of shorter progression free survival (PFS) and overall survival (OS) {39; 108}. 
As reported in the study of Hanamura and colleagues, the frequency of Amp1q21 
increases with disease progression and at relapse was significantly higher than in newly 
diagnosed MM (Figure 5).  
Figure 5: Proportion of cells with Amp1q21 at diagnosis and relapse.  
 
Many data also demonstrated that the gain of 1q21 is also different in the different 
stage of the disease (Table 3). 
Table 3: 1q21 amplification in different stages of disease 
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A German group found that the clinical course of patients with more than three copies 
of 1q21 was characterized by a remarkable short PFS and OS, whereas exactly three 
copies of 1q21 were associated with only a marginal effect on outcome {81}. However 
the Arkansas group reported that patients with more than three copies of 1q21 at 
diagnosis had similar 5-year event-free survival (EFS) and OS compared with those 
with three copies of 1q21 {73} (Figure 6). The clinical translation of this finding is still 
under discussion, since patients with amplifications of 1q21 can’t benefit from 
alternative therapeutic strategies such as thalidomide {110}. 
  
 
Figure 6: A Kaplan-Meier analysis of EFS (left) and OS (right) is displayed in relation to no Amp1q21 
(up to 2 copies of 1q21, n = 124) or Amp1q21 (3 or more copies of 1q21, n = 102) in patients treated 
with a regimen containing thalidomide and in relation to no Amp1q21 (n = 150) or Amp1q21 (n = 103) 
in patients treated with a regimen without thalidomide. Thal+ indicates patients treated with thalidomide; 
Thal-, patients treated without thalidomide. 
 
The cellular and molecular mechanisms of 1q21 amplifications are not well understood 
and to date the relevant genes on 1q are not fully explored. Both aCGH and GEP 
studies have identified one region of proximal 1q with a marked enrichment of genes 
showing a gain and/or amplification which spans approximately a region of 10-15 Mb 
corresponding to a 1q21-23 amplicon in MM {77}. In detail GEP studies found that 
cases with 1q21 gains showed significantly altered expression of genes involved in 
Unfolded Protein Response (UPR), including upregulation of chaperone gene CLN3, 
UBAP2L, and UBE2Q1, proteasome degradation gene PSMD4 and CASP4 gene 
involved in UPR-induced apoptosis {78}. Integrating GEP and DNA variation copy 
number variation data, several independent studies revealed that numerous 1q21 genes 
are copy number sensitive in MM {77;79}. Because UPR induced apoptosis plays an 
 
 
 
2 copies 
3 copies 
4 copies 
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important role in the sensitivity of malignant cells to bortezomib, these studies strongly 
suggest that bortezomib resistance gene overexpression is associated with 1q21 
chromosome gains. Recently, Shaughnessy et al. reported that hyperexpression of 
proteasome PSMD4 (Proteasome 26S subunit, non-ATPase-4) residing on chromosome 
1q21 was a novel high-risk feature in myeloma treated with Total Therapy 3 {80}. The 
same group identified a strong prognostic association with an increased level of 
CKS1B (CDC28 protein kinase regulatory subunit 1B), located on 1q21 chromosome, 
suggesting that it may contribute to disease progression {111-112}. Fonseca and 
colleagues, assessing the 1q21 gain by FISH and the increased expression of CKS1B 
by GEP on two separated cohorts of patients respectively (n=159, n=67), showed that 
neither 1q21 gain nor increased CKS1B expression are independent prognostic factors 
in MM and also 1q21 gain has a more significant impact on the survival than CKS1B 
overexpression but importantly they didn’t find evidence for a copy number-driven 
expression of CKS1B {72}. Another candidate gene located on the 1q21 chromosome is 
MUC1 (Mucin1). Several studies reported that MUC1 is detected on the majority of 
MM cell lines, MM patient cells and MM B cells {113-114} and its levels are related to 
MM disease burden. It is aberrantly expressed in MM cells and there is one early study 
that supports a model in which the inhibition of MUC1 had a synergistic effect with 
Bortezomib to kill Bortezomib resistant cells{115}. Also MCL1 (Myeloid cell leukemia 
1), a BCL2 family member, maps to 1q21 chromosome and it is considered a critical 
survival factor for MM {104}. Zhang et al. showed a rapid activation of apoptosis if only 
MCL-1 was inhibited, even with continuous expression of other antiapoptotic proteins. 
This gene may be an attractive therapeutic target {104}. BCL9, located on chromosome 
1q, is frequently a target of amplification and is associated with aberrant        
expression {77; 109}. In the work of Mani and colleagues BCL9 is overexpressed in a 
subset of MM cells and it plays fundamental roles in tumor progression but they didn’t 
observe a significant relationship between BCL9 DNA copy number and mRNA 
expression in MM patients. Thus, additional mechanisms are involved in the up-
regulation of    BCL9 {109}. The last interesting gene emerged as a candidate target is 
PDKZ1. The over-expression of this gene is reported in a variety of carcinomas {116} 
but its role in the tumorigenesis is still unknown. This gene in primary MM tumor is 
frequently amplified and Inoue and coworkers suggested that PDZK1 is one of 
potential targets for chromosomal gain of 1q21 region, likely associated with drug 
resistance phenotype in MM {117}. In summary, although these findings suggest that 
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1q21 locus harbors target genes associated with myelomagenesis, the essential target 
genes for chromosomal gain involving 1q21 region in MM remains obscure. 
Furthermore, the absence of focal amplifications involving this region strongly suggests 
that more than a single candidate may represent the driver event responsible for poor 
outcome of this group of MM patients. Thus, the identification of critical 1q21 
“Achilles heel” vulnerabilities may yield a comprehensive catalog of the potential 
therapeutic targets for these high-risk MM patients and provide a rationale for patient 
stratification. 
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The 1q21 amplification is among the most frequent chromosomal aberrations in 
patients with Multiple Myeloma (MM) and is considered a highly poor-risk genetic 
feature correlated with disease progression and drug resistance. So the identification of 
critical 1q21 ‘Achilles heel’ vulnerabilities may yield a comprehensive catalog of the 
potential therapeutic targets and provide a rationale for patient stratification. To 
accomplish these goals we have designed first a high-throughput systematic shRNA 
screen approach in vitro to identify 1q21 genes whose loss of function results in MM 
cell death and/or growth inhibition. This assay provided a list of candidate genes 
implicated in survival or proliferation of MM cells with 1q21 amplification; MCL1, 
UBAP2L, INTS3, LASS2, KRTCAP2, and ILF2. By targeting these six genes with 
specific shRNAs, we performed secondary validation experiments in human myeloma 
cell lines harboring four copies of 1q21 amplicon. The results confirmed that the down-
regulation of these genes caused an important decrease of proliferation and increase of 
apoptosis as well as growth cycle arrest. Then in vivo validation studies identified only 
ILF2 correlated with in vivo survival. This result was confirmed also by GEP analysis 
and clinical outcome studies. Further analyses have focused to investigate the role of 
ILF2 in 1q21 amplified MM. My project has been performed with the tight cooperation 
of Dr. Simona Colla and her group at the Leukemia Department of MD Anderson 
Cancer Center in Houston. 
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Cell lines 
All the cell lines used in this study (OCI-MY5, JJN3, H929, 293T) were purchased from 
American Type Culture Collection (ATCC).  HMCLs and 293T were grown respectively 
in RPMI or DMEM medium supplemented L-glutamine (Gibco®, Life Technologies), 10% 
fetal bovine serum (Gibco®), and 100U/ml penicillin/100 mg/ml streptomycin (Gibco®). 
All the cells were maintained at 37°C in a 5% CO2 atmosphere. 
Xenograft models 
Mice were sacrificed when the tumor was more than 20 mm in diameter following the 
IACUC (Institutional Animal Care and Use Committee) protocol; for subcutaneous tumors 
the maximum allowable size is 20 mm in diameter for a mouse. If the animal is host to 
more than one tumor, this size is the maximum allowable size for all tumors combined. 
Cell survival and proliferation/apoptosis assays 
Cell viability was evaluated every 24 hours by Trypan Blue exclusion assay. This 
evaluation was coupled to static assessment by FACS-based cell cycle analysis for 
quantitative S phase measurements via Propidium Iodide (PI; Sigma-Aldrich®) 
incorporation. Furthermore 4’,6- diamino-2-phenylindole (DAPI; Sigma-Aldrich®) and 
Annexin V (Affimetrix®) staining were adopted for the secondary validation screening 
after 4 days from infection, according to the manufacturer’s instructions, for measurement 
of cell viability and apoptosis. 
High-throughput screening in 96 well format  
To overcome major barriers of transgenesis in multiple myeloma (MM) cells, we have 
developed a high-throughput screening strategy in 96 format based on a single hairpin 
GFP-competition assay in which the differential survival of transduced cells is assayed by 
changes in the percentage of GFP positive cells over a time of 7 days. Using this format we 
are currently able to obtain an efficiency of infection of up to 70% (range 40-70%) in 
established MM cell lines: OCI-MY5 and JJN3. Briefly 1q21 shRNA pGipz lentiviral 
library composed of 532 shRNAs targeting 78 genes (Dharmacon®) was used to transfect 
in 96 wells the 293T cell lines. Each single shRNA is located in a different well but in each 
plate 3 wells were designed for the not silencing negative control and 3 for the positive 
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control. After the high-throughput lentiviral production JJN3 cell line carrying the 1q21 
amplification and OCI-MY5 cell line without the 1q21 amplification were infected 
separately by lentiviral shRNAs, targeting each of 78 copy number-driven amplified 1q21 
genes previously identified by our oncogenomic studies. The screen was done in triplicate 
using a single-shRNA-per-96 well format (an average of 5 sequence-verified GFP-based 
shRNAs for each gene will be used). A GFP competitive assay was adopted to identify the 
only genes whose knockdown decreased the percentage of GFP positive cells (4 days after 
lentiviral infection) over a time of 7 days. The GFP percentage in each plate was detected 
using the Canto II Analyzer (BD Biosciences®). 
Western Blotting 
We performed Western blotting analysis according to standard protocols. Briefly cells 
were lysed in the Mammalian Cell Extraction Buffer (BioVision®) supplemented with 1,4-
Dithiothreitol 1M (BioVision®), Protease Inhibitor Cocktail 500x (BioVision®) and 
Phosphatase Inhibitor Cocktail 20x (Roche®). Whole cell lysates (30µg per cell line) were 
separated using the 4-12% NuPAGE® Bis-Tris Precast Gels (Novex®, Life Technologies) 
with MOPS SDS running buffer (Thermo-Fisher Scientific®) and electro-transferred on 
Nitrocellulose membranes (Bio-Rad®) for 1 hour at 100V on ice. The membranes were 
immunoblotted with primary antibodies overnight and then incubated with horseradish 
peroxidase-conjugated secondary antibodies (Pierce®,Thermo-Fisher Scientific) for 1 hour. 
Immuno-positive bands were visualized by enhanced chemiluminescence (Pierce®, 
Thermo-Fisher Scientific) according to the manufacturer’s instructions. The primary 
antibodies anti-γ-H2AX, anti-pATM, anti-pCHK2, anti-Cleaved Caspase 3, anti-β-Actin, 
anti-pNBS1, anti-Cleaved PARP and anti-YB1 came from Cell Signaling Technologies® 
(CST),  anti-vinculin was purchased from Sigma-Aldrich®; the anti-RNA binding protein 
and the heterogeneous nuclear ribonuclearproteins antibodies came from Santa Cruz 
Technologies®; anti-ILF2 and anti-LamininA were purchased from Millipore® and 
Abcam® respectively. Lastly anti-ILF3 p110 and anti-ILF3 p90 primary antibodies came 
from Origene® and Abcam® respectively. 
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Compound treatment and time course experiments 
Melphalan powder (Sigma-Aldrich®) was resuspended in Dimethyl sulfoxide (DMSO) and 
added in JJN3 growing medium at 25µM concentration. Cells were harvested at the 
indicated time point to be processed for Western blot analysis with the procedure specified 
above. ImageJ software (W.Rasband, NIH) was used to quantify Western blot signals. 
Nuclear-Cytosol fractionation 
Nuclear/Cytosol fractionation was performed as specified in the protocol enclosed in the 
Kit (Biovision®) and 10μg of nuclear and 30μg of cytoplasmic proteins were loaded. 
Immunoprecipitation 
Protein A-agarose (Roche®) was washed twice with 0.1M Phosphate Buffer (Boston 
BioProducts®), before 2 hours incubation with 20μg of target or unspecific antibody 
(Rabbit/Mouse IgG; Santa Cruz®) at 4°C in gentle agitation. For the crosslinking, beads 
were washed three times with 50mg/ml Bovine Serum Albumine (BSA; Sigma-Aldrich®) 
in 1xPBS before the 30 minutes of incubation with 1:1 ratio pH8.2, 0.2M Triethanolamine 
(Sigma-Aldrich®)/Dimethyl pimelimidate dihydro-chloride (Sigma-Aldrich®) at room 
temperature. This incubation was repeated two times with a wash in pH8.2, 0.2M 
Triethanolamine in between. Then beads were incubated in pH8.2, 50mM Ethanolamine 
(Sigma-Aldrich®) for 10 minutes at room temperature for two times with a wash in 1xPBS 
in between. Elution of not specific proteins was carry out with two incubations of 5 
minutes with pH 3.00 1M Glycine (Thermo Fisher Scientific®). Finally, beads were 
washed four times with NP-40 Lysis buffer (Boston BioProducts®) supplemented with 
Phosphatase/Protease inhibitor (Roche®). Cell lysate was resuspended in NP-40 Lysis 
buffer and incubated in ice for 15 minutes. After one cycle of sonication at 20% of the 
power (S400 Misonix Instrument®) 1mg of proteins was used in every single 
immunoprecipitation.  Protein sample and beads were incubated for 3 hours at 4°C in 
gentle agitation and then washed three times with NP-40 Lysis buffer. Proteins were then 
eluted by adding NuPage (Life Technologies®) in a 1:1 ratio for 2 minutes at room 
temperature and then for 5 minutes at 70°C. Before loading gel 2-Mercaptoethanol      
(Bio-Rad®) at 2.5% of the final concentration was added to each sample. 
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Mass spectrometry analysis 
Not Silencing (NS), ILF2#1, ILF2#2 JJN3 cells treated or untreated with 25µM Melphalan 
for 10 hours, were immunoprecipitate for ILF2 protein how described above. 4%-12% 
Agarose gel (Invitrogen®) was used to separate protein and, after that, stained with Silver 
Stain Kit following the vendor protocol (Pierce®). Silver-stained gel pieces were washed, 
destained (using the reagents in the Pierce kit) and digested in-gel with 200ng modified 
trypsin (sequencing grade, Promega®) in 50mM ammonium bicarbonate for 18 hours at 
37ºC.  Resulting peptides were extracted and analyzed by LC-MS/MS on an Orbitrap-Elite 
mass spectrometer (Thermo Scientific®).  Proteins were identified by searching of the 
fragment spectra against the SwissProt (EBI) protein database using Mascot (v 2.3, Matrix 
Science, London, UK). Typical search settings were: mass tolerances, 10 ppm precursor, 
and 0.8d fragments; variable modifications, methionine sulfoxide, pyro-glutamate 
formation; trypsin, up to 2 missed cleavages. As suitable candidates only peptides that 
were not appeared in the control lane were considered.  
RNA-Seq sequencing and analysis 
An initial sequence-level quality assessment was performed using FastQC (version 0.10.1, 
Simon Andrews). The RNA-seq  reads  were  then mapped to the human (GRCh37) 
reference genome using Tophat2{98}, allowing a maximum of two mismatches per 75bp 
sequencing end. The NCBI  RefSeq gene model and HTSeq software (version 0.5.4p2,  
Simon Anders) were  used  to  quantify the gene-level expression levels. The differential 
analyses for gene/isoform expression were analyzed with DESeq2{99}while differential 
splicing was analyzed with rMATS{100}. 
Immunofluorescence 
MM cells were resuspended in 1xPBS, spotted on immunofluorescence slides (Thermo 
Scientific®), fixed for 30 minutes in 4% paraformaldehyde (Sigma-Aldrich®), 
permeabilized in 0.2% Triton X-100 (Promega®) for 5 minutes and blocked in 5% BSA for 
1 hour. Then, cells were stained with anti phospho-γH2AX (Millipore®), or phospho-ATM 
(CST®) primary antibodies. Alexa Fluor-555 and Alexa Fluor-488 (Life Technologies®) 
were used as secondary antibodies. Nuclei were stained with DAPI (Sigma-Aldrich®). 
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Indirect immunofluorescence microscopy  
Cells were spotted on Superfrost Microscope Slides (Fisher Scientific®) via cytospin (1200 
RPM for 7 minutes) and fixed with 4% paraformaldehyde (Sigma-Aldrich®) 10 minutes at 
4°C. After 0.2% TritonX-100 (Promega®) permeabilization, cells were blocked in a 1xPBS 
with 5% BSA and 5% Goat Serum (Sigma-Aldrich®) 1 hour at room temperature. Cells 
were then stained with primary antibodies, diluted in the blocking solution, for 1 hour at 
room temperature and counterstained with secondary antibodies 45 minutes at room 
temperature. Cell nuclei were stained with DAPI before mounting coverslip with ProLong 
Gold Antifade mounting solution (Life Technologies®). Images were collected using a 
wide field and confocal microscope (Nikon Instruments Inc.®) and processed using ImageJ 
software (W.Rasband, NIH). 
Binucleation and Nuclear aberrant structures evaluation 
Cell nuclei were stained using DAPI (Sigma-Aldrich®) and wide field microscope 
transmission light permitted us to highlight cell cytoplasm. The analysis of abnormal 
nuclear morphologies (ANMs) was performed on binucleated cells following the criteria 
described by Fenech {101}. A nucleoplasmic bridge was considered to be the narrow/wide 
chromatin segment connecting two cell nuclei, micronuclei were morphologically identical 
to, but smaller than the cell nucleus, and round or oval protrusions of the nuclear 
membrane, connected to the cell nucleus were classified as bud {101}. 
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High-throughput screening for candidate genes 
To identify novel relevant genes associated with 1q21 gain in Multiple Myeloma (MM)- 
we have analyzed high-resolution array-CGH profiling to determine the genome-wide copy 
number amplification (CNA) patterns of the 254 MM samples deposited in the MMRC 
(Multiple Myeloma Research Consortium) database. Specifically, a systematic method, 
named Genomic Identification of Significant Targets in Cancer (GISTIC), was designed 
and used to analyze chromosomal aberrations in cancer {103}. Using this approach each 
marker was scored according to the mean amplitude and frequency of focal amplification 
across the dataset, and significance values were computed by comparison to the 
distribution of scores obtained by random permutation of the markers across the genome. 
Significant peak regions of amplification (or deletion) were identified using an iterative 
peel-off procedure that distributes the score associated with amplified (or deleted) 
segments among all peaks that overlap them (weighted according to each peak’s score) 
until no new region crosses the significance threshold of q-value ≤0.25 on each 
chromosome. By taking into account the auto-correlation within the GISTIC score profiles, 
we computed for each peak region a confidence interval that is predicted to contain the true 
driver gene or genes with at least 99% probability. Using this method, we have identified 
the minimum 1q21 region recurrently amplified in about 40% of MM patients. Then, these 
results were integrated with expression data of matched MM samples identifying a list of 
78 expressed and copy number-driven amplified genes localized in 1q21 that have been 
enlisted into the screening (Table 4). 
 
 
Table 4: Identification of 78 genes with copy-number driven expression of 254 patients in MMRC database. 
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Bases on this evidence, we performed high-throughput systematic short hairpin RNA 
(shRNA) approach to identify copy number-driven amplified 1q21 genes whose loss of 
expression may result in MM cell death and/or growth inhibition. Primary screen was 
carried out in triplicate using a single-shRNA-per-96 well format. Using this format we 
were able to obtain an efficiency of transduction up to 70% (range 40-70%) in different 
established MM cell lines. Specifically, we used 2 different MM cell lines JJN3 and OCI-
MY5 carrying c-MAF translocation but with and without 1q21 amplification respectively 
{73}. These two cell lines were infected separately by lentiviral shRNAs using a library of 
532 shRNA vectors targeting each of 78 copy number-driven amplified 1q21 genes (Figure 
7).  
Figure 7: Schematic representation of our high-throughput screening strategy in 96-well format. 
After excluding shRNAs that display cytotoxic activity regardless of 1q21 amplification, 
1q21 “Achilles hell” vulnerabilities were defined as genes targeted by at least 2 distinct 
shRNAs, whose downregulation decreased the percentage of GFP-positive MM cells with 
1q21 amplification by at least 20% over a 7-day time frame. Specifically, the percentage of 
GFP-positive cells was evaluated by flow cytometry at day 4 and day 12 after transduction 
(Figure 8). 
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Figure 8: Flow cytometry assay showing four different results of the GFP competitive assay of a 
representative experiment. Percentage of GFP-positive cells was evaluated by flow cytometry at day 4 and 
day 12 after transduction. 
 
A shRNA vector delivering a scrambled sequence was included as negative control for 
each experiment. Using these criteria we were able to eliminate weak and false positive 
hits from further validation and only strongest hits were selected for secondary validation. 
Screen performance in terms of sensitivity and reproducibility has been evaluated and 
standardized by a number of experiments with hairpins silencing either universally or MM-
specific essential genes (Figure 9). 
 
Figure 9: Representative example summarizing the results relative to one 96 well plate used in the high-
throughput screening: 91 genes were not silenced by a single hairpin (one/well), instead 3 universally (PLK1, 
KIF11, and UBB) and 2 MM-specific (PMSB4, INTS3) essential genes showed a decrease in the percentage 
of GFP positive cells over a frame period of 7 days. 
NEGATIVE control 
(not silencing)  
68% 66% 
58% 24% 
POSITIVE control 
(UBB)  
GFP at day 4 GFP at day 12 
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PSMB4 (a well-known MM target)-shRNA was able to impair growth of both JJN3 and 
OCI-MY5 cells and this confirmed the specificity of our powerful approach. Our primary 
screen on 78 amplified genes revealed six prime candidates (Table 5) implicated in 
survival or proliferation of MM with 1q21 amplification: MCL1, INTS3, ILF2/NF45, 
KRTCAP2, UBAP2L, and LASS2. These six genes represented the starting point for 
further studies.  
 
 
Table 5: List of candidates emerged from the high-throughput screening. 
 
Secondary validation in vitro and in vivo and prognostic significance 
Secondary validation is an essential step for high-throughput shRNA screening 
experiments, since the level of complexity reached can generate artifacts or non-specific 
phenotypes. Thus a secondary screen was performed in JJN3 and H929 MM cell lines 
(harboring 4 copies of the 1q21 amplification but carrying c-MAF and MMSET 
translocation respectively) {73} infected by two different shRNA vectors specific for each of 
the six genes. First we evaluated the inhibition level of each candidate by Q-RT PCR 
analysis. The latter confirmed that both shRNAs chosen for the six top genes reduced the 
expression of the respective mRNA, demonstrating their efficiency (Figure 10).  
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Figure 10: Q-RT PCR analysis showed that shRNA effect correlate with  the inhibition level of the 6 
targeted genes in JJN3 (left panel) and H929 (right panel). 
 
Moreover, specific assays showed that the each pair of shRNAs specific for the 6 genes 
affected proliferation/survival and apoptosis of MM cell lines with 1q21 amplification 
(Table 6,Figure 11).  
 
 
GENE SYMBOL
VIABILITY 
(%)
APOPTOSIS 
(%) 
Not silenc 93.6 ± 3.2 8.2 ± 0.9
UBB 63.2 ± 4.3 28.3 ± 0.6
MCL1 (sh#1) 61.1 ± 3.1 30.7 ± 2.4
MCL1 (sh#2) 62.9 ± 3.4 33 ± 2.9
INTS3 (sh#1) 81.4 ± 2.4 16.2 ± 2.1
INTS3 (sh#2) 79.3 ± 3.4 22.8 ± 3.2
UBAP2L (sh#1) 85.7 ± 4.3 17.7 ± 1.7
UBAP2L (sh#2) 85.2 ± 2.1 11.4 ± 1.7
LASS2 (sh#1) 76.5 ± 1.5 13.3 ± 2.1
LASS2 (sh#2) 85.1 ± 2.1 13.1 ± 2.3
KRTCAP2 (sh#1) 85.3 ± 3.2 11.8 ± 1.5
KRTCAP2 (sh#2) 81.1 ± 3.4 16.4 ± 0.9
ILF2 (sh#1) 85.5 ± 2.1 13 ± 0.4
ILF2 (sh#2) 78.5 ± 2.3 14.7 ± 0.8
GENE SYMBOL
VIABILITY 
(%)
APOPTOSIS 
(%) 
Not silenc 86.7 ± 3.22 10.6 ± 1.4
UBB 47.1 ± 3.7 42.1 ± 0.6
MCL1 (sh#1) 38.5 ± 5.2 58.2 ± 1.3
MCL1 (sh#2) 67.3 ± 3.9 25.3 ± 1.1
INTS3 (sh#1) 80.2 ± 2.1 18.1 ± 3.1
INTS3 (sh#2) 79.5 ± 4.4 19.4 ± 2.6
UBAP2L (sh#1) 80.1 ± 1.3 18.2 ± 3.7
UBAP2L (sh#2) 86.1 ± 1.8 11.4 ± 2.2
LASS2 (sh#1) 79.1 ± 2.6 15.4 ± 3.2
LASS2 (sh#2) 78.6 ± 1.9 16.2 ± 3.1
KRTCAP2 (sh#1) 83.3 ± 3.6 12.8 ± 1.5
KRTCAP2 (sh#2) 80.1 ± 2.1 17.8 ± 1.1
ILF2 (sh#1) 81.2 ± 2.7 15.3 ± 3.1
ILF2 (sh#2) 78.5 ± 3.6 17.8 ± 2.9
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Table 6-Figure 11: Secondary validation by high-titer virus in JJN3 (lower panels and table on the left) and 
H929 (lower panels and table on the right) indicating the shRNA effects on cell viability and apoptosis. We 
also included two shRNA vectors as negative and positive controls. Cell viability and apoptosis were 
measured by Trypan Blue exclusion assay and Annexin V staining, respectively. 
The clinical relevance of our genes is critical to figure out their potential prognostic 
impact. For this purpose we decided to analyze the correlation between gene expression 
profiling (GEP) and survival data of 256 MM patients with high-dose melphalan treatment 
followed by tandem autologous transplantation included in the Arkansas database. After 
excluding MCL1, a well known MM survival factor {104}, we highlighted that only 2 of 5 
targeted genes, ILF2/NF-45 (p=0.0156) and UBAP2L (p=0.00552) were significantly 
related with the clinical outcome (Figure 12).  
Figure 12: Kaplan-Meier analysis on 256 patients treated with high-dose Melphalan and tandem autologous 
transplantation on the six genes emerged from the high-throughput screening. 
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Furthermore the tumorigenic potential of JJN3 and H929 infected with the 2 shRNAs for 
the 5 genes was determined in NOD-SCID (non-obese diabetic severe combined 
immunodeficiency) mice by a sub cute injection. A group of mice injected with the two 
MM cell lines (2x106cells/mice; 5 mice/group) carrying the control shRNA was included 
in each experiment too. Control JJN3 cells were able to develop tumors and kill the 100% 
of the mice within less than 30 days. Instead H929 cells needed almost 50 days (Figure 
13). Our approach demonstrated that only the knockdown of ILF2 increased the survival of 
NOD/SCID mice injected with either JJN3 or H929 cells (shRNA 1: p=00.3 and p=0.01; 
shRNA 2: p=0.03 and p=0.01, respectively). Therefore, our study was restricting towards 
ILF2 (NF-45) as candidate gene. 
Figure 13: Survival curves of NOD-SCID mice sub cute injected with control or ILF2 shRNA infected JJN3 
cells (left panel) and with control or ILF2 shRNA infected H929 cells (right panel). 
 
ILF2 (NF45): DNA damage, splicing and genomic instability 
Since we restricted our studies on ILF2 gene, further analyses focused to understand its 
potential role in survival of MM cell lines carrying 1q21 amplification. Thus we submitted 
a RNA sequencing analysis to investigate which pathways were deregulated following 
ILF2 knockdown in JJN3 cell line. The most significant pathways up-regulated or down-
regulated in ILF2 shRNA2 compared to control samples are resumed on Figure 14. We 
could appreciate a dysregulation of cell cycle, RNA metabolism, and RNA splicing, 
telomere and chromosome maintenance pathways.  
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Figure 14: Pathways significantly upregulated (right panel) and downregulated (left panel) emerged from 
RNA-sequencing analysis in ILF-2 knockdown JJN3 cells. Each sample processed in duplicate. 
The cell cycle alteration was also confirmed by FACS analysis on JJN3 cell line, with and 
without ILF2 knockdown (Figure 15A). As reported in literature, we observed that JJN3, a 
p53-deficient cell line, rely on checkpoint kinase 1 (Chk1) to arrest cell-cycle progression 
in the S and G2 phases {102}. Indeed H929, a p53 wild type cell line, showed a stop in G1 
phase of cell cycle (Figure 15B). Analyzing in detail the RNA sequencing data we also 
found a large number of proteins  involved in DNA damage pathway. 
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Figure 15: Flow cytometric analysis of cell cycle distribution following not silencing and the two ILF2 
shRNAs transduction in JJN3 and H929 cells (upper and lower panel). 
Synergistic effect between DNA damage agents and ILF2 knock-down 
Based on RNA sequencing analysis data, we decided to evaluate the DNA signaling 
response activation and apoptosis level after knockdown of ILF2 in MM cells. Western 
blotting analysis on JJN3 and H929 cells, showed that the two different shRNAs, 
ILF2Sh#1 and ILF2Sh#2, have different efficiency in ILF2 down regulation, and this 
effect is directly proportional to the level protein decrease of its partner ILF3 (existing in 
two different isoforms NF90 and NF110). At the same time, ILF2 protein level was 
inversely proportional to the amount of DNA damage signaling, DNA damage response 
(γH2AX, phospho-ChK2, phospho-ATM, phospho-ATR, and phospho-DNAPK) and 
Cleaved Caspase 3, a well-known marker of apoptosis. Therefore Western Blot and 
immunofluoresecence analyses suggest that MM cells depleted of ILF2 accumulate DNA 
damage more easily than the control cells. This trend is confirmed also by the increasing of 
gigantic cells in ILF2 knock-down JJN3 cells versus the control ones (Figure 16).  
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Figure 16: WB analysis for the DNA damage signaling in JJN3 MM cell line was examined 7 days after not 
silencing and shRNAs infection. β-actin was included as control for equal loading  (left panel). Localization 
of γH2AX and p-ATM nuclear foci in single cells was determined 7 days after JJN3 infection. Image 
acquisition was performed by confocal microscopy and post-processing analysis of the images was processed 
using ImageJ software (right panel). 
Binucleation or multinucleation together with Abnormal Nuclear Morphologies (ANMs) 
are very good markers of genomic instability and malignancy. MM ILF2 depleted cells 
showed a significantly higher number of binucleated and multinucleated cells together with 
nucleoplasmic bridge, micronuclei and nuclear buds (ANMs) (Figure 17) due to DNA 
damage activation and DNA repair defects. 
 
Figure 17: ILF2 knockdown in JJN3 resulted in multinucleated phenotypes and abnormal nuclear 
morphologies (ANMs) indicated by arrowheads (right panel). The number of nuclei and ANMs per cell is 
plotted (left panel).   
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Accumulation of γ-H2AX foci, features of genomic instability, together with increased 
apoptosis, could represent an important chance in perspective of cancer treatment, 
especially for those subgroups of patients unresponsive to chemotherapy. To this end, we 
tried to evaluate if the downregulation of ILF2 in MM cells could increase sensitivity to 
DNA damage agents. We decided to treat Not Silencing, ILF2#1 and ILF2#2 JJN3 cells 
with Melphalan, a nitrogen mustard still in use to treat MM patients. Thus, we tried to 
figure out the molecular pathway activation during drug exposure. We treated Not 
Silencing and ILF2#2 JJN3 cells with 25μM Melphalan for 12 hours and, at the indicated 
time points, we collected proteins to perform Western blot analysis on DNA damage 
signaling, DNA damage response and apoptotic pathways (Figure 18). We observed a 
significant increase of γH2AX phosphorylation in ILF2#2 samples compared to the 
control, especially at later time point. On the contrary, the activation of phospho-ATM and 
phospho-NBS1 in ILF2#2 sample seemed weaker overtime rather than Not Silencing one. 
Finally Caspase3 confirmed a stronger apoptosis in ILF2#2 respect Not Silencing cells. 
Quantification of the protein signal together with statistical analysis, clearly confirmed the 
synergistic effect of Melphalan and ILF2 shRNA on JJN3 cells, probably due to an 
impaired activation of DNA damage response (Figure 18). 
To confirm this hypothesis, we designed a drug exposure time point, with the same 
concentration of Melphalan but, this time, we washed out the drug after 6 hours of 
treatment, to follow the cell ability to recover DNA damage (Figure 18).  How expected, at 
starting point the γH2AX content was higher in ILF2#2 respect Not Silencing sample and 
was increasing, having different absolute content, with almost the same kinetics after drug 
exposure in both samples. After Melphalan washed out, the activation of the DNA damage 
response in ILF2#2 resulted once again wicker respect to control JJN3 cells from 6 to 10 
hours, getting even worst after 10 hours (Figure18). As a result of this impairment, we 
observed a certain quantity of unrepaired DNA damage in ILF2 knocked down respect to 
control cells (Figure 18). 
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Figure 18: Schematic representation of the two different time courses (upper panel). WB analysis of the 
expression of activated forms (γH2AX, p-ATM, p-NSB1) of mediator DNA damage proteins and protein 
involved in the apoptosis process (Cleaved Caspase 3, Cleaved PARP) in JJN3 MM cell line was examined 
after Melphalan 25µM with or without wash-out. B-actin was included as control for equal loading (lower 
left and middle panels). Densitometric analysis to evaluate protein amount was performed using ImageJ 
software (lower right panels). 
 
At the opposite side, in a regimen of ILF2 overexpression, the accumulation of γH2AX 
foci was significantly reduced and after 12 hours of Melphalan treatment, myeloma cells 
seemed protected from apoptosis, like indicated by decreasing of cleaved caspase-3 protein 
(Figure 19).   
 
Figure 19: WB analysis of ILF2, γH2AX and Cleaved Caspase-3 following ILF2 overexpression (ILF2-O) 
with and without Melphalan treatment. JJN3 cells infected with a GFP vector were included as a control 
(GFP). Vinculin was included as control for equal loading. 
Results 
 
47 
 
ILF2 interacts with proteins involved in DNA damage response, RNA 
metabolism and splicing 
Trying to figure out the reason why ILF2 knock out can affect the DNA damage response 
of MM cells, we performed an ILF2 immunoprecipitation (IP) in Not Treated and in 25μM 
Melphalan Treated JJN3 cells after 10 hours of treatment and we submitted those samples 
for a mass spectrometric analysis (Figure 20). To obtain a reliable list of potential ILF2 
partner proteins, we only considered peptides that not appeared in the Immunoglobulin 
control lane. We found almost not differences between Not Treated and Treated JJN3 cells 
in terms of ILF2 potential binding proteins. 
 
Figure 20: Separation of proteins by SDS-PAGE. SILAC-labeled cell proteins were separated on a 4-12% 
Agarose gel and stained with the Silver Stain Kit for Mass Spectrometry (Pierce®). The grids overlaid on the 
ILF2 IP samples demonstrate the area taken for individual slices. We excluded from the sampling the 
peptides also presented in the Input lane.  
In order to validate the candidates, we did a Western blot analysis on ILF2-IP to confirm 
the interactions in wild type JJN3 cells. We got a positive outcome for both of ILF3 
isoforms (NF90/110), known ILF2 interacting partners {106-107}. We saw that ILF2 interacts 
with a panel of different RNA proteins (RBPs) including Nucleophosmin (NPM), Y-box-
binding-protein1 (YB-1), Nucleolin, Adenosine Deaminase Acting on RNAs (ADAR1), 
Sam68 and a couple of heterogeneous nuclear ribonuclearproteins (hnRNPs), A1, U like, 
K, C1/C2, F/H, G, which protect cells from DNA damage directly at the site of the damage 
or indirectly stabilizing specific pre-mRNAs {105}(Figure 21). 
25 μM Melphalan 
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Figure 21: Validation by Immunoprecipitation of the mass spectrometry top scoring candidates in JJN3 wild-
type cell line. 
To evaluated if ILF2 is required to ensure alternative splicing and processing of specific 
pre-mRNAs in physiological conditions, the RNA-Sequencing analysis of JJN3 cells 
carrying shRNA targeting ILF2 displayed a specific aberrant RNA splicing pattern 
associated with ILF2 down-regulation, detecting 646 differential splicing events for 500 
genes, among which 46.5% are predicted to produce loss-of-function transcripts that arise 
mainly due to a premature stop codon or an in-frame deletion disrupting known functional 
domains. Interestingly, the differentially spliced transcripts associated to ILF2 
downregulation are enriched in genes directly involved in different DNA damage repair 
pathways, including single-strand base excision, single-strand mismatch, double-strand 
non homologous and homologous repair (Figure 22). These data emphasize our conviction 
on a link between ILF2 and DNA damage regulation. 
Figure 22: RNA-sequencing analysis on JJN3 cells with ILF2 knock-down detected a specific aberrant RNA 
splicing pattern. 
Interestingly, RNA-Sequencing analysis of JJN3 cells under Melphalan treatment 
displayed different RNA splicing events, not emerged from the previous one, associated 
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with DNA damage activation, detecting 1,363 differentially splicing events for 989 genes, 
mostly involved in the DNA repair of several classes of DNA damage, sister chromatid 
cohesion, cell cycle regulation and mRNA processing pathways, consistent with our 
hypothesis that ILF2 might promote splicing events after DNA damage activation (Figure 
23). 
Figure 23: RNA-Sequencing analysis of JJN3 cells with ILF2 knock-down treated with Melphalan detected 
new splicing events associated to DNA damage.  
 
ILF2 regulates YB-1 nuclear translocation  
As ILF2 and ILF3 interact with RNA and contributes to RNA gene regulation at the levels 
of transcription, splicing, export and translation {118}, to check if ILF2 down-regulation 
could affect protein translation or stability of its partners, we treated Not Silencing and 
ILF2sh#1 and sh#2 with 25µM Melphalan for 10 hours and we analyzed their protein 
levels by Western blot. With the exception of ILF3 p110 isoform, which showed a 
translational modulation proportional to the amount of ILF2 protein abrogated by the two 
different shRNAs, the ILF2 knock-down with or without Melphalan treatment did not 
modify ILF2 interactome suggesting that ILF2 does not bind alternative partners during 
DNA damage conditions (Figure 24).  
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Figure 24: Western blot of ILF2 interactome with and without Melphalan treatment. Β-actin and vinculin 
were included as control for equal loading. 
Since some of ILF2 interacting proteins, like Nucleolin, YB-1 and Sam68 are known to 
shuttle between cell cytoplasm and nucleolus when DNA damage occurs {105}, we checked 
if ILF2 knock-down could affect their dynamic localization by immunofluorescence. We 
treated again Not Silencing and ILF2sh#2 JJN3 cells with Melphalan, as described above, 
and we stained cells with anti γH2AX antibody, as DNA damage marker, looking for 
impaired localization of this ILF2 partners before and after DNA damage. We found no 
change in localization between Not Silencing and ILF2sh#2, before and after Melphalan 
treatment, for almost all the tested proteins discovered to bind ILF2, except for YB-1. 
Looking at Y-box-binding-protein 1 by wide-field microscopy in fact, we observed an 
increase of this protein in Not Treated JJN3 cell nuclei after DNA damage induction. 
Instead under the same condition, no YB-1 nuclear signal was detected before and after the 
DNA damage in the ILF2sh#2 JJN3 cells (Figure 25). 
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Figure 25: Localization of γH2AX and YB-1 foci in single cells was determined at 10 hours with (lower 
panel) and without (upper panel) Melphalan treatment. Image acquisition was performed by wide-field 
microscopy and post-processing analysis of the images was processed using ImageJ software. 
Moreover, to assess what we observed by wide-field microscopy we decided to stain JJN3 
Not Silencing and shILF2#2, with ILF2 and YB-1 antibody and to analyze the localization 
of these proteins by confocal microscopy. In the control cells, ILF2 presented a staining 
almost nuclear and diffuse, shifting in brilliant dots after DNA damage. In the same cells 
instead, YB-1 was almost cytoplasmic, with few nuclear discrete dots that definitely 
increased after Melphalan. Finally, the shILF#2 staining permanently demonstrate that no 
YB-1 protein can be recruited in the cell nuclei of MM cells after DNA damage (Figure 
26). 
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Figure 26: Localization of ILF2 and YB-1 nuclear foci in single cells determined at 10 hours with (lower 
panel) and without (upper panel) Melphalan treatment. Image acquisition was performed by confocal 
microscopy and post-processing analysis of the images was processed using ImageJ software. The scale bar 
represents 10µm. 
 
To examine closely the impaired YB-1 localization induced by ILF2 knockdown, we 
decided to perform a cytoplasm-nuclear fractionation Western blot, in Not Silencing and 
ILF2#2 JJN3 cells, before and after Melphalan treatment. Not Silencing control cells 
showed that, as expected, YB-1 is able to translocate to the nucleus after DNA Damage 
and, surprisingly, also ILF2 showed the same behavior. On the contrary after ILF2    
knock-down (ILF2 sh#2 sample), the nuclear quantity of YB-1 protein held steady before 
and after DNA Damage (Figure 27). Then, we wondered what would have happened to this 
protein shuttling, after the same treatment with Melphalan, but in a setting of ILF2 
overexpression. We over expressed ILF2 protein in JJN3 cells and we repeated the same 
experiment checking again, by Western blot, the YB-1 and ILF2 nuclear protein amount 
before and after DNA damage. As expected, the control showed similar results for the Not 
Silencing control cells previously used. Interestingly at the opposite side, the 
overexpression of ILF2 was quite completely cytoplasmic and, as is shown in Figure 27, 
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strongly enhanced the YB-1 nuclear translocation after DNA Damage induction. Finally 
we can conclude that under Melphalan treatment YB-1 nuclear translocation was impaired 
in ILF2 depleted cells and was potentiated after ILF2 overexpression. 
Figure 27: Cytoplasm-nuclear fractionation Western blot on JJN3 cell line infected with scrambled construct 
(Not Silencing) and ILF2 sh#2, and with GFP and ILF2 overexpressed vectors (left panels). Vinculin and 
Lamin-A were included as control for equal loading on the whole and nuclear protein extracts respectively. 
Densitometric analysis to evaluate the protein loading performed using ImageJ software is presented on the 
right side. 
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Despite significant efforts towards the development of risk stratification strategies for 
patients with Multiple Myeloma (MM), the capacity to molecularly predict the natural 
history of these patients is still limited. Many studies have shown that genetic alterations 
especially t(4;14) translocation, loss of the short arm of chromosome 17 and amplification 
of chromosome 1q21 are associated with poor outcome and represent independent adverse 
predictors of shorter progression-free survival (PFS) and overall survival (OS){39; 108}. The 
1q21 amplification is among the most frequent chromosomal aberrations in patients with 
myeloma and is considered a very poor-risk genetic feature that is especially correlated 
with disease progression and drug resistance {73; 75; 76}. Although the 1q21 locus contains a 
large number of possible candidate genes that are related to disease pathogenesis including 
PSMD4, CKS1B, BCL9, MCL1, MUC1, PDZK1 {80;72; 111-112; 109; 104; 113-116}, so far the 
relevant genes on 1q21 remain unclear and the absence of focal amplifications involving 
this region strongly suggests that more than a single candidate may represent the driver 
event responsible for poor outcome in this group of myeloma patients in response to 
different therapeutic regimens. Thus this study focused first on the identification of critical 
1q21 “Achilles heels” vulnerabilities for MM, then on their functional validation. Our in-
depth bioinformatics analysis of MM genome has generated a high priority list of 78 
amplified and overexpressed genes localized in 1q21 (Table 7). These genes have been 
enlisted into a systematic shRNA screen in vitro to identify critical 1q21 candidates whose 
loss of function results in the selective death and/or growth inhibition of MM cells carrying 
the 1q21 amplification and c-MAF translocation (JJN3 cell line) but not in MM cells 
without 1q21 amplification (OCI-MY5 cell line) {73} (Figure 7). With our 96-well high-
throughput screening strategy, six genes were emerged as key 1q21 targets; MCL1, INTS3, 
ILF2, KRTCAP2, UBAP2L, LASS2. Secondary validation experiments in the MM cell 
lines JJN3 and H929 (harboring 4 copies of the 1q21 amplicon) {73} confirmed for all the 
six candidates by two different shRNAs the quality of our approach (Figure 10) and mainly 
the impairment of cell proliferation/survival and apoptosis (Figure 11 and Table 6). Thus 
our efforts have been directed forward the functional validation of the six hits resulted 
from our preliminary screen. After excluding MCL1 gene, known factor implicated in 
myeloma cell survival{104}, the subsequent studies on the remaining five candidate genes 
have pointed out a potential role of ILF2/NF45 in DNA damage response and RNA 
splicing in 1q21 amplification context. 
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Interleukin enhancer binding factor 2 (ILF2), also named NF45, belongs to the NFAT 
(Nuclear Factor of Activated T cells) complex in a heterodimeric core with ILF3 
(NF90/NF110) that is widely expressed in many cell-types and tissues {118}. ILF2 shows a 
predominant expression in the nucleus mostly in testis, brain, and kidney but it results 
overexpressed in Lymphoma and Leukemia transformed cell lines {119}. ILF2 interacts with 
numerous proteins and RNAs partecipating in transcription, RNA transport, mRNA 
stability, and translation {118}. Apart from regulation of mRNA metabolism, ILF2 has been 
implicated in the regulation of other pathways including DNA damage response{118; 120}, 
microRNA processing {121} and viral infection {122; 123}. 
In our study, the target validation of ILF2 in NOD-SCID mice showed that ILF2 down-
regulation had a significant impact on in vivo survival of JJN3 and H929 cell lines (Figure 
13). Therefore, we sought to further characterize the ILF2 role in 1q21-amplified 
myeloma. As shown in other systems {106; 118}, myeloma cells depleted for ILF2 displayed 
giant multinucleated cells and abnormal nuclear morphologies (nucleoplasmic bridges, 
nuclear buds and micronuclei). Such mitotic defects and aberrant morphologies are linked 
to the disruption of genomic integrity due to DNA damage activation and DNA repair 
defects. Following ILF2 down-regulation we observed a significant activation of the ATM-
dependent signaling pathway, but differently from other findings on different cellular 
systems {118; 120}, it resulted ATR and DNA-PK independent (Figure 16). Notably, we 
observed also an accumulation of γH2AX foci (Figure16), consistent with an accumulation 
of DSBs (Double Strand Breaks), which led to cell cycle arrest either in G2/M or in G0/G1 
(Figure 15), depending on TP53 status {102} (absent in JJN3 and wild-type in H929, 
respectively) and Caspase 3-mediated apoptosis (Figure 16). 
Thus, to determine whether ILF2 is involved in the regulation of DNA damage signaling 
and DNA repair pathways in MM cells with 1q21 amplification, we evaluated if ILF2 
down-regulation increased myeloma sensitivity to DNA-damaging agents. Employing 
Melphalan treatment as activator of DNA damage signaling, ILF2-depleted MM cells 
subjected to continuous Melphalan treatment showed synergetic accumulation of phospho-
H2AX foci and increased caspase-3-induced apoptosis (Figure 18). Similar results were 
obtained in drug wash-out experiments, in which the kinetics of DNA damage foci 
resolution was evaluated following Melphalan withdrawal (Figure 18). Our findings 
indicated that ILF2 down-regulation was be able to potentiate Melphalan-induced DNA 
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damage activation and apoptosis in JJN3 cell line. Conversely, further increase of ILF2 
expression significantly reduced the accumulation of phospho-H2AX foci and protected 
MM cells from Melphalan-induced apoptosis (Figure 19). 
Although several studies indicated an association between ILF2 and cancer, the detailed 
role and mechanism are still unknown {124-126}. Recently, it was reported that ILF2 over-
expression predicted poor survival in non-small cell lung cancer and in glioma {127-128}. 
Accordingly, our clinical correlative studies showed that higher levels of ILF2 expression 
correlated with poor survival of MM patients treated with high-dose Melphalan followed 
by tandem autologous transplantation (p=0.0156, Figure 12).  
Collectively, these data support the view that ILF2 is involved in the regulation of DNA 
damage response pathways and are consistent with its role as a mediator of double-strand 
DNA break repair. To understand the molecular mechanisms underlying the involvement 
of ILF2 in DNA damage response in MM cells, we performed ILF2 immunoprecipitation 
experiments combined with mass spectrometry in the JJN3 cell line (Figure 20). Further 
validation of ILF2 interactome confirmed that beside its known binding partners 
NF90/NF110, ILF2 interacts with numerous RNA binding proteins (RBPs) including 
NPM, YB-1, nucleolin, ADAR1, and various heterogeneous nuclear ribonucleoproteins 
(hnRNPs), which are directly involved in DNA repair, maintenance of genome stability, 
and regulation of DNA damage response by modulating alternative splicing and stability of 
specific pre-mRNAs (Figure 21) {105}. Thus, we first evaluated if ILF2 is required to ensure 
alternative splicing and processing of specific pre-mRNAs in physiological conditions. The 
RNA-Sequencing analysis on JJN3 cells carrying shRNA targeting ILF2, displayed 
differentially spliced transcripts directly involved in DDR (DNA Damage Response) of 
several types of DNA damage, including single-strand base excision, single-strand 
mismatch, double-strand non homologous and homologous repair, supporting the tight 
connection between ILF2 and DNA damage regulation (Figure 22), as previous studies 
reported in different systems {118; 120}. 
Since recent studies reported that DNA damage affects splicing decision up- or down-
regulating a significant fraction of m-RNAs through modulation of the interactions 
between RBPs and their target mRNA molecules modifying mRNA stability {129-130}, we 
determined following exposure to Melphalan treatment if ILF2 is recruited to promote 
splicing events after DNA damage activation. Indeed RNA-Sequencing analysis of JJN3 
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cells treated with Melphalan and depleted for ILF2, showed different RNA splicing events 
associated with DNA damage activation, mostly involved in the DNA repair of several 
classes of DNA damage, sister chromatid cohesion, cell cycle regulation and mRNA 
processing pathways (Figure 23), accordingly with previous findings where RNA 
metabolism and DNA repair pathways are functionally crossed {130}. 
Next, to determine the mechanistic bases of how ILF2 down-regulation impairs RNA 
splicing of DNA repair genes both in physiological condition and after DNA damage 
activation, we evaluated if ILF2 is required for the stability or nuclear localization of its 
interactors, which may shuttle from the cytoplasm to the nucleus in response to DNA 
damage {105}. ILF2 down-regulation was associated with a dramatic post-transcriptional 
destabilization of its partner NF110 without affecting NF90 or RBP and hnRNP levels 
(Figure 24) and significantly impaired the nuclear localization of YB-1 after Melphalan 
treatment (Figure 25-27) without modifying the subcellular localization of the other 
interacting proteins. Notably, further increase of ILF2 expression strongly activated YB-1 
nuclear localization after DNA damage treatment (Figure 27).  
These findings demonstrate that ILF2 levels modulate the nuclear localization of YB-1 in 
response to DNA damage and gain added significance in light of recent findings showing 
that YB-1 contributes to disease progression, survival, and drug resistance in MM         
cells {131}. 
Although it was reported that the aberrant up-regulation of ILF2 expression could be 
associated to a malignant phenotype in Leukemia and Limphomas {119}, as well as it is 
known that ILF2 is involved in several tumors including breast cancer, lung cancer, 
glioma, HCC and colorectal cancer {126-128; 131-134}, further studies are necessary to figure 
out better its role. Notably, to date the role of ILF2 in MM has not been yet investigated. 
Therefore, all these data provide evidence that ILF2 is a novel 1q21 gene target in MM 
with a pivotal role in DNA damage repair and in the localization of YB-1. Importantly, our 
findings raise ILF2 in a critical position for the regulation of physiological and DNA 
damage-induced mRNA splicing process. In summary, we believe that ILF2 might be a 
novel therapeutic target to enlist into prognostic and drug discovery efforts for a more 
effective classification and management of MM patients with 1q21 amplification who do 
not benefit from recent treatment improvements.
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